Table 1.
Patient Demographics and Clinical Characteristics
| Angio‐Guided PPCI n = 216 | IVUS‐Guided PPCI n = 125 | P Value | |
|---|---|---|---|
| Male sex, n (%) | 136 (63.0) | 93 (74.4) | 0.032 |
| Age, y | 61.4 ± 11.6 | 60.0 ± 12.9 | 0.259 |
| Past history, n (%) | |||
| Diabetes | 71 (32.9) | 34 (27.2) | 0.330 |
| Hypertension | 111 (51.4) | 64 (50.4) | 0.911 |
| Dyslipidemia | 24 (11.1) | 28 (22.4) | 0.007 |
| Myocardial infarction | 13 (6.0) | 12 (9.6) | 0.281 |
| Previous PCI | 12 (5.6) | 13 (10.4) | 0.130 |
| Previous CABG | 2 (0.9) | 0 (0) | 0.534 |
| Smoking | 125 (57.9) | 94 (75.2) | 0.002 |
| Congestive heart failure | 4 (1.9) | 3 (2.4) | 0.710 |
| Cerebral infarction | 16 (7.4) | 6 (4.8) | 0.493 |
| Chronic renal insufficiency | 6 (2.8) | 3 (2.4) | 1.000 |
| Laboratory tests at admission | |||
| TC, mg/dL | 178.0 ± 42.0 | 172.6 ± 40.0 | 0.407 |
| TG, mg/dL | 134.8 ± 105.3 | 128.4 ± 90.1 | 0.690 |
| HDLC, mg/dL | 44.3 ± 10.9 | 43.9 ± 10.9 | 0.797 |
| LDLC, mg/dL | 103.1 ± 38.2 | 103.3 ± 36.3 | 0.980 |
| CK‐MB initial, ng/mL | 37.3 ± 68.3 | 49.2 ± 79.5 | 0.149 |
| Creatine, mg/dL | 1.02 ± 0.94 | 1.01 ± 0.78 | 0.874 |
| Hb, g/dL | 14.2 ± 3.3 | 15.3 ± 13.6 | 0.255 |
| hs‐CRP, mg/dL | 1.95 ± 3.82 | 1.77 ± 3.72 | 0.757 |
| BNP, pg/dL | 128.9 ± 336.1 | 138.6 ± 284.2 | 0.824 |
| Initial vital sign | |||
| SBP, mmHg | 122 ± 37 | 125 ± 35 | 0.569 |
| DBP, mmHg | 74 ± 22 | 76 ± 24 | 0.521 |
| HR, beat/min | 74 ± 23 | 80 ± 22 | 0.038 |
| LVEF by echocardiography, % | 48.0 ± 11.5 | 45.1 ± 9.1 | 0.009 |
| Killip classification II or more, n (%) | 51 (23.6) | 25 (20.0) | 0.500 |
| Symptom‐to‐door time, min, median (IQR) | 180 (109, 305) | 154 (85, 305) | 0.994 |
| Discharge medication, n (%) | |||
| Aspirin | 216 (100.0) | 124 (99.2) | 0.367 |
| Clopidogrel | 215 (99.5) | 124 (99.2) | 1.000 |
| Cilostazol | 38 (17.6) | 9 (7.2) | 0.009 |
| Statin | 119 (55.1) | 75 (60.0) | 0.427 |
| β‐blocker | 139 (64.4) | 86 (68.8) | 0.477 |
| ACEI or ARB | 148 (68.5) | 81 (64.8) | 0.550 |
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP, B‐type natriuretic peptide; CABG, coronary artery bypass graft; CK‐MB; creatine kinase‐MB; DBP, diastolic blood pressure; Hb, hemoglobin; HDLC, high‐density lipoprotein cholesterol; HR, heart rate; hs‐CRP, high sensitive CRP; IQR, interquartile range; IVUS, intravascular ultrasound; LDLC, low‐density lipoprotein cholesterol; LVEF, left‐ventricular ejection fraction; PCI, percutaneous coronaryintervention; PPCI, primary percutaneous coronary intervention; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.